<p><em>代表超过 285% 的年同比收入增长</em></p>
<p><em>销售增长得益于 2025 年发货 40 台扫描仪，较 2024 年的 12 台有所增加</em></p>
<p><em>预计年末将处于强劲的财务状况，以支持持续增长</em></p>
<p>加利福尼亚州诺瓦托 --（商业新闻）--QT Imaging Holdings, Inc.（OTCQB: QTIH）（“QT Imaging” 或 “公司”）是一家从事创新体内成像系统的研究、开发和商业化的医疗设备公司，今天确认已完成 40 台扫描仪的发货，并达成了 2025 年超过 1800 万美元的收入指引。</p>
<p>“2025 年对 QT Imaging 来说是一个过渡年，我们从早期商业化转向规模化执行。我们达成了目标，并按照计划发货扫描仪，展示了市场的日益接受和运营的严谨。我们预计在 2025 年结束时将处于显著更强的财务状况，预计年末现金至少为 1000 万美元，而 2024 年末为 120 万美元，” 首席执行官 Raluca Dinu 博士表示。“我想感谢我们的董事会、团队、所有商业合作伙伴和投资者的持续支持，帮助我们为公司的持续增长做好准备。”</p>
<p><strong>2025-2026 年销售展望</strong></p>
<p>公司重申 2026 年收入为 3900 万美元（发货 80 台扫描仪）。这一目标符合根据与其战略业务和分销合作伙伴 NXC Imaging, Inc.（佳能医疗系统美国公司的全资子公司）修订的分销协议所需的最低订单数量，以及与沙特阿拉伯的 Gulf Medical Co.之前宣布的分销协议。</p>
<p>2025 年 12 月 23 日，公司还向美国证券交易委员会提交了一份 8-K 表格的当前报告，其中包括截至 2025 年 9 月 30 日、6 月 30 日和 3 月 31 日以及 2024 年 12 月 31 日的未经审计的临时合并损益表和综合损失表的副本。这些财务报表提供了理解公司在 2025 年增强盈利能力和显著减债所需的所有信息。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条的定义的前瞻性声明。这些声明包含 “将” 和 “预计” 等词语，或其否定形式或类似术语，包括（但不限于）关于 QT Imaging 乳腺声学 CT 成像技术、产品销售增长、预计收入和现金状况的声明。前瞻性声明涉及某些风险和不确定性，实际结果可能与任何此类声明中讨论的结果有重大差异。这些风险包括但不限于：QT Imaging 乳腺声学 CT 扫描仪使用的研究结果，QT Imaging Holdings 销售和部署 QT Imaging 乳腺声学 CT 扫描仪的能力，扩展产品到新领域或产品的能力，商业化技术的能力，政府批准，意外事件妨碍产品的全面文档和 “推向市场” 计划，行业趋势和波动，客户需求和采购量的变化，供应商的不可预测性，吸引和留住合格人员的能力，以及将产品销售提升到生产水平的能力。可能导致实际结果不同的其他因素在 QT Imaging Holdings 向 SEC 提交的文件以及其不时提交或提供的其他当前和定期报告的 “风险因素” 标题下和其他部分中进行了讨论。本新闻稿中的所有前瞻性声明均基于截至本日期的信息，QT Imaging Holdings 不承担更新任何前瞻性声明的义务。</p>
<p><strong>关于 QT Imaging</strong></p>
<p>QT Imaging Holdings, Inc.是一家公开的（OTCQB: QTIH）医疗设备公司，专注于使用低频声波进行创新体内成像系统的研究、开发和商业化。QT Imaging Holdings, Inc.致力于改善全球健康结果。其战略基于医疗成像对疾病的检测、诊断和治疗至关重要，并且应该是安全、可负担、可及，并以患者体验为中心。有关 QT Imaging Holdings, Inc.的更多信息，请访问公司网站 www.qtimaging.com。</p>
<p>Breast Acoustic CTTM 是 QT Imaging Holdings, Inc.的一个附属商标。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjQ5OTEwNjdyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjQ5OTEwNjdyMQ"/></p>
<p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20251224991067/en/</p>
<p>如需投资者和媒体咨询，请联系：</p>
<p><strong>Stephen Kilmer</strong></p>
<p>投资者关系负责人</p>
<p>Stephen.Kilmer@qtimaging.com</p>
<p>电话： (646) 274-3580</p>
<p><strong>Jay Jennings</strong></p>
<p>首席财务官</p>
<p>Jay.Jennings@qtimaging.com</p>
<p>来源：QT Imaging Holdings, Inc.</p>

<p>QT Imaging Holdings, Inc. 宣布将在 2025 年发运 40 台乳腺声学 CT™扫描仪，标志着同比 285% 的收入增长。公司预计到 2025 年底将拥有强劲的财务状况，预计现金达到 1000 万美元。对于 2026 年，QT Imaging 的目标是实现 3900 万美元的收入，并发运 80 台扫描仪。公司强调其战略合作伙伴关系和前瞻性的增长计划</p>

<p><em>Represents Year-Over-Year Revenue Growth of More than 285%</em></p>
<div class="lb-trans"><p><em>代表超过 285% 的年同比收入增长</em></p>
</div><p><em>Sales Increase Driven by Shipment of Forty Scanners in 2025, up from Twelve in 2024</em></p>
<div class="lb-trans"><p><em>销售增长得益于 2025 年发货 40 台扫描仪，较 2024 年的 12 台有所增加</em></p>
</div><p><em>Expects to End Year in a Strong Financial Position to Support Continued Growth</em></p>
<div class="lb-trans"><p><em>预计年末将处于强劲的财务状况，以支持持续增长</em></p>
</div><p>NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (OTCQB: QTIH) (“QT Imaging” or the “Company”), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today confirms that it finalized the shipment of 40 scanners and met its revenue guidance of more than $18 million in 2025.</p>
<div class="lb-trans"><p>加利福尼亚州诺瓦托 --（商业新闻）--QT Imaging Holdings, Inc.（OTCQB: QTIH）（“QT Imaging” 或 “公司”）是一家从事创新体内成像系统的研究、开发和商业化的医疗设备公司，今天确认已完成 40 台扫描仪的发货，并达成了 2025 年超过 1800 万美元的收入指引。</p>
</div><p>“2025 was a transitional year for QT Imaging as we moved from early commercialization to scaled execution. We met our objectives and shipped scanners in line with our plan, demonstrating growing market adoption and operational discipline. We expect to exit 2025 in a significantly stronger financial position, with projected year end cash of at least $10 million, compared to $1.2 million at the end of 2024,” said Dr. Raluca Dinu, Chief Executive Officer. “I would like to thank our board of directors, our team, all our commercial partners, and investors for their continued support as we position the Company for sustained growth.”</p>
<div class="lb-trans"><p>“2025 年对 QT Imaging 来说是一个过渡年，我们从早期商业化转向规模化执行。我们达成了目标，并按照计划发货扫描仪，展示了市场的日益接受和运营的严谨。我们预计在 2025 年结束时将处于显著更强的财务状况，预计年末现金至少为 1000 万美元，而 2024 年末为 120 万美元，” 首席执行官 Raluca Dinu 博士表示。“我想感谢我们的董事会、团队、所有商业合作伙伴和投资者的持续支持，帮助我们为公司的持续增长做好准备。”</p>
</div><p><strong>2025-2026 Sales Outlook</strong></p>
<div class="lb-trans"><p><strong>2025-2026 年销售展望</strong></p>
</div><p>The Company reiterates $39 million in revenue in 2026 (shipment of 80 scanners). This target is in accordance with the minimum order quantities to be shipped per its Amended Distribution Agreement with its strategic business and distribution partner, NXC Imaging, Inc., a wholly owned subsidiary of Canon Medical Systems USA, as well as its previously announced distribution agreement with Gulf Medical Co. in Saudi Arabia.</p>
<div class="lb-trans"><p>公司重申 2026 年收入为 3900 万美元（发货 80 台扫描仪）。这一目标符合根据与其战略业务和分销合作伙伴 NXC Imaging, Inc.（佳能医疗系统美国公司的全资子公司）修订的分销协议所需的最低订单数量，以及与沙特阿拉伯的 Gulf Medical Co.之前宣布的分销协议。</p>
</div><p>On December 23, 2025, the Company also furnished a Current Report on Form 8-K to the U.S. Securities and Exchange Commission, which includes copies of its unaudited pro forma condensed consolidated statement of operations and comprehensive loss as of and for the three months ended each of September 30, June 30, and March 31, 2025, and December 31, 2024. These financial statements are provided to present all information necessary to understand the Company’s enhanced profitability and meaningful debt reduction in 2025.</p>
<div class="lb-trans"><p>2025 年 12 月 23 日，公司还向美国证券交易委员会提交了一份 8-K 表格的当前报告，其中包括截至 2025 年 9 月 30 日、6 月 30 日和 3 月 31 日以及 2024 年 12 月 31 日的未经审计的临时合并损益表和综合损失表的副本。这些财务报表提供了理解公司在 2025 年增强盈利能力和显著减债所需的所有信息。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding QT Imaging Breast Acoustic CT imaging technology, and product sales growth and projected revenues and cash position. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, governmental approvals, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends, and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel, and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging Holdings’ filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.</p>
<div class="lb-trans"><p>本新闻稿包含根据《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条的定义的前瞻性声明。这些声明包含 “将” 和 “预计” 等词语，或其否定形式或类似术语，包括（但不限于）关于 QT Imaging 乳腺声学 CT 成像技术、产品销售增长、预计收入和现金状况的声明。前瞻性声明涉及某些风险和不确定性，实际结果可能与任何此类声明中讨论的结果有重大差异。这些风险包括但不限于：QT Imaging 乳腺声学 CT 扫描仪使用的研究结果，QT Imaging Holdings 销售和部署 QT Imaging 乳腺声学 CT 扫描仪的能力，扩展产品到新领域或产品的能力，商业化技术的能力，政府批准，意外事件妨碍产品的全面文档和 “推向市场” 计划，行业趋势和波动，客户需求和采购量的变化，供应商的不可预测性，吸引和留住合格人员的能力，以及将产品销售提升到生产水平的能力。可能导致实际结果不同的其他因素在 QT Imaging Holdings 向 SEC 提交的文件以及其不时提交或提供的其他当前和定期报告的 “风险因素” 标题下和其他部分中进行了讨论。本新闻稿中的所有前瞻性声明均基于截至本日期的信息，QT Imaging Holdings 不承担更新任何前瞻性声明的义务。</p>
</div><p><strong>About QT Imaging</strong></p>
<div class="lb-trans"><p><strong>关于 QT Imaging</strong></p>
</div><p>QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the Company’s website at www.qtimaging.com.</p>
<div class="lb-trans"><p>QT Imaging Holdings, Inc.是一家公开的（OTCQB: QTIH）医疗设备公司，专注于使用低频声波进行创新体内成像系统的研究、开发和商业化。QT Imaging Holdings, Inc.致力于改善全球健康结果。其战略基于医疗成像对疾病的检测、诊断和治疗至关重要，并且应该是安全、可负担、可及，并以患者体验为中心。有关 QT Imaging Holdings, Inc.的更多信息，请访问公司网站 www.qtimaging.com。</p>
</div><p>Breast Acoustic CTTM is a trademark of an affiliate of QT Imaging Holdings, Inc.</p>
<div class="lb-trans"><p>Breast Acoustic CTTM 是 QT Imaging Holdings, Inc.的一个附属商标。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjQ5OTEwNjdyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251224991067r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251224991067/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20251224991067/en/</p>
</div><p>For investor and media inquiries, please contact:</p>
<div class="lb-trans"><p>如需投资者和媒体咨询，请联系：</p>
</div><p><strong>Stephen Kilmer</strong></p>
<div class="lb-trans"><p><strong>Stephen Kilmer</strong></p>
</div><p>Head of Investor Relations</p>
<div class="lb-trans"><p>投资者关系负责人</p>
</div><p>Stephen.Kilmer@qtimaging.com</p>
<div class="lb-trans"><p>Stephen.Kilmer@qtimaging.com</p>
</div><p>Direct: (646) 274-3580</p>
<div class="lb-trans"><p>电话： (646) 274-3580</p>
</div><p><strong>Jay Jennings</strong></p>
<div class="lb-trans"><p><strong>Jay Jennings</strong></p>
</div><p>Chief Financial Officer</p>
<div class="lb-trans"><p>首席财务官</p>
</div><p>Jay.Jennings@qtimaging.com</p>
<div class="lb-trans"><p>Jay.Jennings@qtimaging.com</p>
</div><p>Source: QT Imaging Holdings, Inc.</p>
<div class="lb-trans"><p>来源：QT Imaging Holdings, Inc.</p>
</div>

QT Imaging 宣布将在 2025 年交付四十台乳腺声学 CT™扫描仪，并实现其收入预期 | QTIH 股票新闻